Four EGFR-Mutated Lung Cancers That Changed Form After Osimertinib — Case 2
This lung cancer diagnosis at a glance
- Subtype
- Small Cell Lung Cancer
- Biomarkers
- EGFR exon 19 deletion; TP53 p.R110P; acquired MET amplification
- Sex
- female
- Treatment
- targeted therapy, chemotherapy and immunotherapy
- Outcome
- In Memory
Treatment course, step by step
- She received osimertinib for 14 months.
- After small cell transformation with acquired MET amplification, she received tepotinib with osimertinib.
- After progression 5 months later, she received carboplatin and etoposide with atezolizumab for 7 months.
What happened, in summary
A 61-year-old woman with EGFR-mutated lung cancer was treated with osimertinib for 14 months. At progression, the tumor had transformed into small cell lung cancer. The EGFR exon 19 deletion was still present, and testing also found an acquired MET amplification. A TP53 p.R110P alteration had been present in the original tumor. Because of the MET amplification, she received the MET inhibitor tepotinib together with osimertinib. The cancer progressed again 5 months later. She then switched to carboplatin and etoposide chemotherapy combined with the PD-L1 inhibitor atezolizumab. She continued that regimen for 7 months before her death. Her treatment course required repeated changes as the lung cancer developed both a new histologic form and a new resistance alteration during targeted therapy.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- EGFR Mutation Lung Cancer 112 stories
- Atezolizumab for Lung Cancer 18 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer